ES038 / Elpiscience - LARVOL DELTA

ES038, a novel NKCE Molecule Targeting LILRB4 in AML via Dual Engagement of NKG2A and NKG2C (SITC 2025) - "ES038 exhibited preferable drug developability and mouse PK profile. In vivo, ES038 treatment reduced leukemic tumor growth and extended mice survival.Conclusions This first-in-class NKCE, leveraging dual NKG2A/C engagement, offers a promising strategy in AML and other LILRB4 positive hematologic malignancies."

Acute Myelogenous Leukemia • Oncology • CD123 • CD33 • HLA-E • IFNG • IL3RA • KLRC1 • KLRD1 • LAMP1 • LILRB4